The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction

被引:47
作者
González, P
Garcia-Casto, M
Reguero, JR
Batalla, A
Ordóñez, AG
Palop, RL
Lozano, I
Montes, M
Alvarez, V
Coto, E [1 ]
机构
[1] Hosp Univ Cent Asturias, Genet Mol Lab, Inst Invest Nefrol, Oviedo 33006, Spain
[2] Hosp Univ Cent Asturias, Serv Cardiol, Oviedo, Spain
[3] Hosp San Agustin, Hematol Serv, Aviles, Spain
[4] Hosp Cabuenes, Serv Cardiol, Gijon, Spain
[5] Hosp Univ Virgen Arrixaca, Serv Cardiol, Murcia, Spain
[6] Hosp Univ Virgen Arrixaca, Serv Immunol, Murcia, Spain
关键词
D O I
10.1136/jmg.2005.035071
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: A myocyte enhancer factor 2A (MEF2A) mutation that segregated with coronary artery disease/ myocardial infarction (CAD/MI) in a large family has recently been described. Missense mutations in sporadic coronary artery disease patients were also reported. These data suggest that mutations in exons 7 and 11 of MEF2A cause CAD/MI, though the association was refuted by another study. Objective: To analyse the genetic variation of exons 7 and 11 in a large cohort of Spanish CAD/MI patients and controls. Methods and results: A rare polymorphism, P279L, was detected both in patients and controls. Carriers of the 279Leu allele had a threefold risk of suffering CAD/MI compared with controls ( p = 0.009; odds ratio = 3.06 (95% confidence interval, 1.17 to 8.06)). In the controls the allele was found only in those under 50 years of age. Exon 11 showed a high degree of heterogeneity caused by a polyglutamine (CAG) n polymorphism, but no significant differences in genotype or allelic frequencies were found. Conclusions: The 279Leu allele appears to be a genetic risk factor for CAD/MI in the population studied. This effect could be the result of a reduced transcriptional activity on MEF2A with 279Leu.
引用
收藏
页码:167 / 169
页数:3
相关论文
共 13 条
[1]  
AKANAZA H, 2003, CIRC RES, V92, P1079
[2]   Polymorphic trinucleotide repeat in the MEF2A gene at 15q26 is not expanded in familial cardiomyopathies [J].
Bachinski, LL ;
Abchee, A ;
Durand, JB ;
Roberts, R ;
Krahe, R ;
Hobson, GM .
MOLECULAR AND CELLULAR PROBES, 1997, 11 (01) :55-58
[3]   Transcription factor MEF2A mutations in patients with coronary artery disease [J].
Bhagavatula, MRK ;
Fan, C ;
Shen, GQ ;
Cassano, J ;
Plow, EF ;
Topol, EJ ;
Wang, Q .
HUMAN MOLECULAR GENETICS, 2004, 13 (24) :3181-3188
[4]   Coronary heart disease and polymorphisms in genes affecting lipid metabolism and inflammation [J].
Cambien F. .
Current Atherosclerosis Reports, 2005, 7 (3) :188-195
[5]   Myocyte enhancer binding factor-2 expression and activity in vascular smooth muscle cells - Association with the activated phenotype [J].
Firulli, AB ;
Miano, JM ;
Bi, WZ ;
Johnson, D ;
Casscells, W ;
Olson, EN ;
Schwarz, JJ .
CIRCULATION RESEARCH, 1996, 78 (02) :196-204
[6]   Atherosclerosis [J].
Lusis, AJ .
NATURE, 2000, 407 (6801) :233-241
[7]   A SIMPLE SALTING OUT PROCEDURE FOR EXTRACTING DNA FROM HUMAN NUCLEATED CELLS [J].
MILLER, SA ;
DYKES, DD ;
POLESKY, HF .
NUCLEIC ACIDS RESEARCH, 1988, 16 (03) :1215-1215
[8]   Polyglutamine expansion diseases: failing to deliver [J].
Morfini, G ;
Pigino, G ;
Brady, ST .
TRENDS IN MOLECULAR MEDICINE, 2005, 11 (02) :64-70
[9]   Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor [J].
Naya, FJ ;
Black, BL ;
Wu, H ;
Bassel-Duby, R ;
Richardson, JA ;
Hill, JA ;
Olson, EN .
NATURE MEDICINE, 2002, 8 (11) :1303-1309
[10]   Mutation of MEF2A in an inherited disorder with features of coronary artery disease [J].
Wang, LJ ;
Fan, C ;
Topol, SE ;
Topol, EJ ;
Wang, Q .
SCIENCE, 2003, 302 (5650) :1578-1581